

## **Scientific Abstract**

A phase I open label, dose-escalating, single center study comparing three dose levels ( $5 \times 10^5$ ,  $5 \times 10^6$ , and  $5 \times 10^7$  p.f.u.) of Modified Virus Ankara-Human Papillomavirus-Interleukin-2 (TG4001) given by intramuscular injection weekly for 3 weeks prior to definitive local therapy for CIN3. Patients will receive a single course of therapy. The objective of this study is to determine safety and the maximum tolerated and biologically active dose. Dose escalation will continue to the MTD or  $5 \times 10^7$  dose level, whichever occurs first. Patients will be assessed for cellular and humoral responses to E6 and E7.